Research analysts covering Enlivex Therapeutics.
Recent press releases and 8-K filings for ENLV.
Enlivex Therapeutics Announces RAIN Token Listing on WhiteBIT
ENLV
New Projects/Investments
Delisting/Listing Issues
- Enlivex Therapeutics Ltd. announced the listing of its primary treasury asset, the RAIN token, on the WhiteBIT cryptocurrency exchange, effective January 21, 2026.
- The listing on WhiteBIT, described as the largest European cryptocurrency exchange by traffic, is anticipated to expand market access and enhance secondary market liquidity for the RAIN token.
- This move supports Enlivex's digital asset treasury strategy, making it the first publicly-listed company to center its treasury reserve on the RAIN token.
Jan 26, 2026, 1:01 PM
Enlivex's RAIN Token Listed on WhiteBIT Cryptocurrency Exchange
ENLV
Delisting/Listing Issues
New Projects/Investments
- Enlivex Therapeutics' primary digital treasury asset, the RAIN token, was listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026.
- WhiteBIT is identified as the largest European cryptocurrency exchange by traffic, serving over 35 million customers globally.
- This listing is expected to expand market access and enhance secondary market liquidity for the RAIN token, supporting Enlivex's digital asset treasury strategy.
- Enlivex is the first publicly-listed company to have developed a treasury strategy centered on RAIN, aiming to provide investors with exposure to the token.
Jan 26, 2026, 1:00 PM
Enlivex Therapeutics Lists RAIN Token on KuCoin Exchange
ENLV
New Projects/Investments
Delisting/Listing Issues
- Enlivex Therapeutics Ltd. announced that its treasury asset, the RAIN token, was listed on the KuCoin cryptocurrency exchange effective January 6, 2026.
- KuCoin is a global cryptocurrency exchange serving over 40 million users and consistently ranks among the top ten globally.
- This listing is expected to expand global market access and secondary liquidity for Enlivex's primary digital asset treasury holding.
- The RAIN token is the primary asset of Enlivex's digital asset treasury, a strategy intended to provide investors with exposure to RAIN.
Jan 7, 2026, 1:02 PM
Enlivex Therapeutics' RAIN Token Listed on KuCoin Exchange
ENLV
New Projects/Investments
Delisting/Listing Issues
- Enlivex Therapeutics' primary digital treasury asset, the RAIN token, was listed on the KuCoin cryptocurrency exchange effective January 6, 2026.
- KuCoin is a global cryptocurrency exchange serving over 40 million users worldwide and consistently ranks among the top ten cryptocurrency exchanges globally.
- The listing is expected to expand global market access and secondary liquidity for Enlivex's RAIN token treasury holdings.
- Enlivex is the first publicly-listed company to have developed a treasury strategy centered on the RAIN token.
Jan 7, 2026, 1:00 PM
Enlivex Therapeutics Ltd. to Vote on Reverse Share Split, Board Classification, and Executive Equity Bonus
ENLV
Delisting/Listing Issues
Executive Compensation
Board Change
- Enlivex Therapeutics Ltd. has scheduled an Extraordinary General Meeting for February 3, 2026, to address several proposals.
- Shareholders will vote on a reverse share split with a ratio ranging from 1-for-2 to 1-for-20, aimed at meeting Nasdaq's minimum bid price requirement and attracting institutional investors. The Board will determine the exact ratio within 12 months post-meeting.
- A proposal to classify the Board of Directors into three classes with staggered three-year terms will also be presented.
- The agenda includes approving an equity bonus for Executive Chairman Shai Novik, comprising restricted share units representing 2.5% of the fully diluted share capital upon grant, with an additional 0.5% contingent on a capital increase of at least $500 million. This bonus is not consistent with the company's Compensation Policy and exceeds the maximum permitted value by four times.
Dec 18, 2025, 9:30 PM
Enlivex to Host Fireside Chat on RAIN Token Strategy and Allocetra Development
ENLV
New Projects/Investments
- Enlivex Therapeutics Ltd. will host a virtual fireside chat on December 11, 2025, at 11:00 am ET.
- The discussion will focus on Enlivex's digital asset strategy built around RAIN token accumulation and its plans to advance the clinical development of AllocetraTM.
- Executive Chairman Shai Novik will provide an update following the company's recently closed $212,000,000 private placement.
- Enlivex is adopting a treasury strategy centered on RAIN as its primary reserve asset, aiming to provide investors with exposure to RAIN.
Dec 4, 2025, 1:02 PM
Enlivex Therapeutics Ltd. Announces Closing of Private Placement and Board Changes
ENLV
New Projects/Investments
Board Change
- Enlivex Therapeutics Ltd. completed a private placement on November 24, 2025, generating $212.0 million in gross proceeds.
- The net proceeds from the private placement will be primarily used to purchase RAIN and establish the company's cryptocurrency treasury operations as part of its digital asset treasury strategy.
- Andrew Singer resigned from the Board of Directors, and Matteo Renzi, former Prime Minister of Italy, was appointed to the Board of Directors, both effective upon the closing of the private placement.
- The company will continue its clinical development of Allocetra™ for knee osteoarthritis.
Nov 26, 2025, 1:03 PM
Enlivex Therapeutics Announces Closing of Private Placement
ENLV
New Projects/Investments
Board Change
- Enlivex Therapeutics Ltd. announced the closing of a $212,000,000 private investment.
- The company intends to use the net proceeds to implement the world's first RAIN prediction markets token digital asset treasury strategy and continue clinical development of Allocetra™ for knee osteoarthritis.
- Mr. Matteo Renzi, former Prime Minister of Italy, has joined the Enlivex Board of Directors.
Nov 26, 2025, 1:00 PM
Enlivex Appoints Former Italian PM to Board and Secures $212M Private Placement
ENLV
Board Change
New Projects/Investments
- Enlivex Therapeutics Ltd. announced the appointment of Mr. Matteo Renzi, former Prime Minister of Italy, to its board of directors, effective November 24, 2025.
- This appointment follows a $212,000,000 private placement (PIPE) for the purchase and sale of 212,000,000 ordinary shares at $1.00 per share, representing an 11.5% premium from the closing price on November 21, 2025.
- Enlivex intends to use the net proceeds from the PIPE to implement the first RAIN prediction markets token treasury strategy, positioning itself as the first publicly-listed company to develop such a strategy with RAIN as its primary treasury reserve asset.
Nov 24, 2025, 3:00 PM
Enlivex Therapeutics Reports Q3 2025 Financials and Positive Osteoarthritis Trial Data
ENLV
Earnings
New Projects/Investments
Guidance Update
- Enlivex Therapeutics Ltd. reported a net loss of $(2,205) thousand for the three months ended September 30, 2025, and an accumulated deficit of approximately $134.6 million as of that date.
- The company announced positive three-month topline data on August 18, 2025, for its AllocetraTM Phase I/II trial in moderate-to-severe knee osteoarthritis, demonstrating a 24% reduction in knee pain and 26% improvement in knee function.
- As of September 30, 2025, Enlivex held approximately $18.2 million in cash and cash equivalents and short-term bank deposits, with current resources projected to fund operations through the end of 2026.
- Enlivex has reprioritized its clinical focus to inflammatory and auto-immune verticals, reducing its workforce by approximately 50% and seeking external collaborations for its sepsis and oncology programs.
Nov 14, 2025, 9:30 PM
Quarterly earnings call transcripts for Enlivex Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more